Insulin-like growth factor receptor-1 (IGF-1R) inhibition could be a relevant therapeutic approach in small cell lung cancer (SCLC) given the importance of an IGF-1R autocrine loop and its role in DNA damage repair processes. We assessed IGF-1R and pAkt protein expression in 83 SCLC human specimens. The efficacy of R1507 (a monoclonal antibody directed against IGF-1R) alone or combined with proteins involved in proliferation, angiogenesis and survival. Finally, we identified that the nucleotide excision repair pathway (NER) was mediated after exposure to R1507-CDDP and R1507-IR in vitro and in vivo. In conclusion, adding R1507 to the current standard Cisplatin-IR doublet reveals remarkable chemo-and radiosensitizing effects in selected SCLC models and warrants to be investigated in the clinical setting.
Abstract:
Insulin-like growth factor receptor-1 (IGF-1R) inhibition could be a relevant therapeutic approach in small cell lung cancer (SCLC) given the importance of an IGF-1R autocrine loop and its role in DNA damage repair processes. We assessed IGF-1R and pAkt protein expression in 83 SCLC human specimens. The efficacy of R1507 (a monoclonal antibody directed against IGF-1R) alone or combined with proteins involved in proliferation, angiogenesis and survival. Finally, we identified that the nucleotide excision repair pathway (NER) was mediated after exposure to R1507-CDDP and R1507-IR in vitro and in vivo. In conclusion, adding R1507 to the current standard Cisplatin-IR doublet reveals remarkable chemo-and radiosensitizing effects in selected SCLC models and warrants to be investigated in the clinical setting.
Introduction:
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and is the cause of death in 90-95% of affected individuals within 5 years(1). Over the past 20 years, progress in treatment has been limited and the standard of care is still therapy combining cisplatin plus ionizing radiation (IR) and cisplatin-based polychemotherapy for locally advanced and extended disease, respectively (2) . New strategies based on a better understanding of SCLC biology are urgently needed.
The presence of an Insulin Growth factor-1 (IGF1)/Insulin Growth factor-1
Receptor (IGF-1R) autocrine loop is thought to be instrumental in driving the aggressive course of SCLC (3) . This receptor is a well-recognized promoter of malignant transformation, proliferation and survival through the transduction of Phosphoinositide 3-kinase (PI3K)/Akt and Mitogen-activated protein kinase (MAPK) pathways (4) . Furthermore, the IGF-1R pathway has been implicated in resistance to DNA damaging agents, suggesting its role in DNA damage repair (5) (6) (7) (8) . Previous studies on in vitro models of SCLC suggest that inhibition of the IGF-IR pathway might enhance the sensitivity of SCLC to chemotherapy through the inhibition of PI3K-Akt activation (9, 10) . However, these studies did not include in vivo validation and comprehensive molecular analyses on the interaction between chemotherapy and IGF-1R inhibitors. As a result, there is little rationale to support the four phase I/II studies that are currently investigating agents targeting the IGF-1R/IGF axis in context mimicking the clinical course of patients treated for SCLC (IR combined with chemotherapy). We first evaluated the expression of the phosphorylated forms of IGF-1R and of Akt in 83 human SCLC specimens. We then assessed the efficacy of R1507 against selected SCLC cell lines and examined the consequences on IGF-1R downstream signaling. We also investigated whether R1507 could potentiate the effects of cisplatin and IR in vitro and in vivo. Finally, we conducted an integrated genomic and functional analysis to explore the adaptive mechanisms occurring (i) after long-term versus short-term R1507 exposure and (ii) with Cisplatin-and IR-R1507 combinations.
Materials and Methods:
Human established SCLC cell lines NCI-H146, NCI-H69 and NCI-H526 were obtained from the American Type Culture Collection (ATCC-LGC Standards, authentication by ATCC using short tandem repeat profiling). No further authentication was performed on these cell lines: they were passaged within the six months of the purchase. All cell lines cultured in the following medium:
RPMI 1640 (GIBCO® -Invitrogen) supplemented with 1% GlutaMAX, 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells growing in floating aggregates were maintained in plastic flasks and incubated at 37°C in 5% CO IGF-1R (11) . Toxicity in the clinical setting has already been described elsewhere (12) .
Cisplatin was purchased from Mylan Pharmaceuticals and stored at room temperature. Its chemical formula is Cis-PtCl 2 (NH 3 ) 2 and its molar mass is 301.1 g/mol.
Clonogenic survival assay: Clonogenic survival assays was performed as previously described (13) . A total irradiation dose of 2 Gy was delivered using a linear accelerator (200-kV X-ray irradiator, dose rate = 0.96 Gy min-1) within the hour after seeding. Colonies consisting of at least 50 viable cells were estimated 21 days post treatment. The surviving fraction was normalized to the corresponding untreated control. Each experiment was repeated three times.
Western Blot (WB): WB were performed, as previously described (13) . Signals were detected using the Super Signal® West Pico chemoluminescent system (Pierce (1:50 dilution, Cell Signaling). A section of normal human breast was used as a negative control whereas an invasive ductal carcinoma that was positive for IGF1R protein expression was included as a negative control. The scoring system used to interpret immunohistochemical staining was based on the distribution and the intensity of staining: no staining or slight staining in < 10% cells (0), slight staining in > 10% cells ('1+'), marked staining in 10-50% cells ('2+') and strong staining in > 50% cells ('3+') as previously described (14) . All the IHC analyses were centrally performed in a blinded manner by a senior pathologist (J.C.). of three independent experiments and were compared using the Student's t test. The synergy effect between different conditions was assessed using the two-way ANOVA interaction test. Tumor sizes were compared using Student's t tests. Tumor growth delay (days) was analyzed using the Kaplan Meier method, considering any event as the moment when the tumor volume had attained 5-fold the baseline volume (RTV5).
For all the tests performed, a p value of less than 0.05 was considered statistically significant, and all tests were two-tailed. The statistical analyses were conducted using the R statistical software and Bioconductor packages (affy, limma). IGF-1R and pAkt were frequently expressed in human SCLC tissue specimens.
We assessed IGF-1R expression and Akt phosphorylation in one of the largest cohort of SCLC human specimens (83 patients). Positive IGF-1R immunohistochemical staining (Fig.1A) was observed in 44 patients (53%), while pAkt (Fig.1B) was detected in 31 patients (37%). A total of 17 (21%) and 22 (26%) of all tumors exhibited a minimum of 2+ staining intensity for IGF-1R and pAkt, respectively.
Concomitant expression of both proteins was present in 24 samples (29%)
suggesting that IGF pathway could be a relevant target in SCLC.
R1507 downregulated IGF-1R protein expression and disrupted its downstream signaling in selected SCLC cell lines
Three SCLC cell lines were selected according to their high basal IGF1R protein expression and their specific mutation profiles: H146 cells are mutated for MAP2K4 (c.814_891del78), whereas H69 cells are mutated for both PIK3CA (c.317_325del9) and c-Met (c.2962C>T) (Cosmic database). WB analyses showed a down-regulation of IGF-1R protein expression in the presence of R1507 (200nM) in all the selected cell lines (Fig.1 C) .
R1507 decreased IGF-1-induced downstream effector pAKT in H526 and H146 cells but not in H69 cells (Fig.1D) . R1507 also inhibited ligand-induced phosphorylation of MEK in H526 cells. However, the MAPK pathway (pMAPK, pMEK) appeared to be stimulated by R1507 in a dose-dependent manner in H146 cells. 
R1507 inhibited colony formation of selected SCLC cell lines in vitro.
Exploring the sensitivity of selected SCLC cell lines to R1507, we observed a 35% and 45% relative reduction in colony formation of H526 cells (P < .0001) and H146 cells (P < .0001), respectively ( Fig.2A) . No significant reduction in the colony-forming capacity was observed in H69 cells (data not shown). Although we did not study any SCLC cell lines without IGF-1R basal expression, such feature does not appear to be correlated with sensitivity to R1507. Indeed, R1507 treatment had no effect on H69 cells, while these cells present IGF1R basal expression (Fig.1D) . Interestingly, only the cell lines (H526 and H146) with IGF-1R gene amplification exhibited sensitivity to R1507 whereas those devoid of IGF1R gene amplification (H69) did not respond to R1507 (Fig.2B ).
R1507 sensitized H146 and H526 cells to cisplatin and IR effects.
Since cisplatin (CDDP)-based chemotherapy and IR are the standard treatments for SCLC, we investigated whether R1507 could enhance their efficacy in SCLC cell lines. To formally assess the synergy relationship, two-way ANOVA were computed.
We observed that the combination of R1507 and CDDP decreased their colonyforming capacity by 90% and 87% in H526 and H146 cells, respectively (P<.001) (Fig.2C) . We observed a synergistic inhibitory effect of the CDDP-R1507 combination on the colony-forming capacity of H146 cells (two-way ANOVA interaction test; P=.008) and an additive inhibitory effect in H526 cells (two-way ANOVA interaction test; P=.691). The R1507-IR combination decreased the colony-forming capacity by 87% and 88% in H526 and H146 cells, respectively (P<.001) (Fig.2D) . We also noted a synergistic effect of R1507-IR on the colony-forming capacity of H146 cells (twoway ANOVA interaction test; P=.0001), and an additive inhibitory effect in H526 cells Cisplatin (CDDP) combined with IR remains the standard of care for the treatment of limited-stage SCLC. We herein observe that the addition of R1507 to CDDP-IR resulted in a 32% and 45% relative reduction in the colony-forming capacity compared to CDDP-IR in H146 and H526 cells, respectively (P<.001 and P<.0001) (Fig.3) .
The addition of R1507 to CDDP or IR induced non-significant delays in tumor growth in vivo.
To evaluate the delay in tumor growth according to the various treatment conditions in vivo, we assessed the RTV5 in H526 and H146 xenografts (Fig.4A,B and Supplementary Fig.1&2 ). Single agent R1507 induced a non-significant delay in tumor growth in H526 and in H146 cells (Supplementary table.1) . Similarly, the R1507-CDDP and R1507-IR combination produced a non-significant delay in tumor growth in both H146 cells and H526 cells (Fig.4B) .
The triple combination CDDP-IR-R1507 caused a dramatic delay in tumor growth in H526 xenografts as compared with the CDDP-IR combination.
The triple combination R1507-CDDP-IR produced a significant delay in tumor growth compared to the standard CDDP-IR regimen in H526 cells (median RTV5: R1507-Cisplatin-IR=50 days vs. Cisplatin-IR=34 days, P=0.006) (Fig.4A,B) . Notably, the To evaluate whether R1507 could efficiently inhibit IGF-1R in tumor tissue, we examined IGF-1R expression in H526-xenografted mice at different treatment times.
We observed an expected decrease in IGF-1R expression on day 2, but a secondary increase on day 7 (Fig.5A ). This did not appear to be attributable to a lack of R1507 availability on day 7 since the product half-life in mice is estimated at 10 days(11).
We thus hypothesized that some adaptive mechanisms occurred upon R1507 exposure and resulted in the secondary increase in IGF1R expression on day 7. The overall regulation of gene expression induced by R1507 in H526 xenografts at the following time points: baseline (vehicle), R1507 day 1 and R1507 day 7. A total of 2396 probe sets were differentially expressed at R1507 day 1, whereas only 254 probe sets were differentially expressed at R1507 day 7. Interestingly, only 6.7% (n= 156) of the initially deregulated probe sets (R1507 day 1) remained differentially expressed at R1507 day 7 (Fig.5B, Supplementary Fig.3 (Supplementary table. 2). Interestingly, the downregulation of the MAPK pathway for R1507 day 1 was consistent with our previous results in vitro (Fig.1D) . However, some pathways like MAPK signaling appeared to be inversely deregulated between R1507-day 1 and R1507-day 7 (Supplementary table. 2), suggesting a role in the escape to R1507 alone in vivo.
To confirm the micro-array results at the protein level, we performed low-scale protein arrays (Fig.5C, Supplementary Fig.4 ). CDDP, IR, CDDP-R1507 and IR-R1507 (Fig.6A,B, Supplementary Fig.5&6,   Supplementary table.2) . To investigate the biological basis of the gene expression variation, we computed the overlap between the differentially expressed probes and gene set databases.
The probes differentially expressed exclusively in the CDDP-R1507 combination were associated with downregulation of the NER pathway (Nucleotide Excision Repair) (P=0.02) (through decreases in ERCC1, XAB2 and RAD23A gene expression) and upregulation of the apoptotic mitochondrial response to DNA damage pathway (through gene expression modifications in BCL2L1 and IFI6) (P=0.04) (Fig.6A, Supplementary table.2, Supplementary Fig.5 ).
The probes that were exclusively differentially expressed in the R1507-IR combination were associated with a downregulation of the TGF-Beta pathway (Fig.6B, Supplementary table.2, Supplementary Fig.6 ), suggesting that the IR-R1507 combination induced the downregulation of this pathway.
We then showed that the R1507-CDDP combination decreased ERCC1 but not XPA protein expression in H526 cells (Supplementary Fig.7A ), and also decreased cleaved caspase 9 expression (Supplementary Fig.7C ). When we examined the effect of R1507-IR on the TGF-beta pathway, we did not observe any impact on SMAD4 protein expression (Supplementary Fig.7D ). We next investigated whether the R1507-IR combination could modify ERCC1 (and XPA at the protein expression level. Interestingly, the R1507-IR combination also decreased ERCC1 but not XPA protein expression in H526 cells (Supplementary Fig.7C ). We did not observe a significant effect of R107 monotherapy in H526 xenografts.
Interestingly, long lasting responses have been observed with anti-IGF1R agents delivered in monotherapy, in patients diagnosed with Ewings sarcoma or with adrenocortical carcinoma (17, 18) . However, such responses have not yet been described in the SCLC setting. In this study, we observed that -compared to the short-term setting, the chronic administration of R1507 as a single agent led to both sustained IGF-1R pathway activity and to the concomitant relief of multiple alternative signaling pathways including the HER family receptors, angiogenesis, STATs, etc. MCT-12-1067 insulin receptor in our model(21). These results require to be validated in human specimens to be confirmed. Since most antineoplastics are delivered over the long term and in a recurrent manner, we believe that greater emphasis should be given to long-term preclinical analyses when evaluating a new drug.
The latter findings also support strategies combining anti-IGF-1R drugs with other antineoplastics. In this regard, the long-lasting R1507-induced sensitizing effect with CDDP and IR is noteworthy. This can be partially explained by the role of IGF-1R in DNA damage repair processes. A large body of literature already exists regarding the influence of IGF-1R on DNA damage repair through ATM (7, 8) . Here, we describe that the R1507-CDDP and R1507-IR combinations were associated with a downregulation of the NER pathway in vitro and in vivo. Given the importance of methylcellulose as previously described [12] Colony-forming assays were performed in methylcellulose as previously described [12] 
